Htg Molecular Diagnostics, Inc. · OTC:HTGMQ
Htg Molecular Diagnostics — Investor Presentation (July 2021)
23 slides from Htg Molecular Diagnostics's investor presentation, Jul 20, 2021
Slide 1: HTG Molecular Diagnostics Corporate Overview July 2021
Advancing the Promise of Precision Medicine HTG Molecular Diagnostics Corporate Overview July 2021 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements 2 This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding the benefits and capabilities of our transcri
Slide 3: Welcome to HTG
Welcome to HTG HTGisa company ing novel drug and profiling diagnostics to determine the right therapy for the right patient HTG Molecular - life science tools and diagnostics based on proprietary ies and i i HTG Therapeutics — therapeutic discovery using transcriptomic profiling, bioinformatics and
Slide 4: HTG plans to solve two big problems – efficacy and safety
4 HTG plans to solve two big problems – efficacy and safety 3% Commercial Efficacy Operational Strategy Safety Commercial Efficacy Safety Strategy Operational Reason for failure in Phase II Reason for failure in Phase III <12% of drugs entering clinical trials succeed* Approx $985M per drug approved
Slide 5: HTG Therapeutics is planning to disrupt the paradigm
HTG Therapeutics is planning to disrupt the paradigm Pushing iterative knowledge learning upstream 5 Source: The Skeptical Chemist Level of knowledge 2 – 3 years 3 – 5 years <1 year 2 -4 years Level of knowledge Registration and market introduction Chemistry Search for active substances, application
Slide 6: Early and often transcriptome profiling can disrupt drug development
6 Early and often transcriptome profiling can disrupt drug development Integrating big data expression profiling to improve therapeutic candidates
Slide 7: Comprehensive RNA profiling platform technology
7 Comprehensive RNA profiling platform technology HTG’s advanced new profiling capabilities expected to open up exciting new market opportunities New New
Slide 8: HTG has evolved its platform technology
HTG has evolved its platform technology: Advanced full transcriptome profiling combined with machine learning driven chemistry expected to enable more effective drug and companion diagnostic discovery across broad disease areas 8
Slide 9: HTG is well positioned in the emerging field of RNA therapeutics
HTG is well positioned in the emerging field of RNA therapeutics 20X increase in targets vs. current protein paradigm expected 9 Nature Reviews, August 2018
Slide 10: Multiple target strategies for drug discovery
Multiple target strategies for drug discovery 10
Slide 11: HTG Therapeutics – RNA based drug discovery
HTG Therapeutics – RNA based drug discovery Pioneering transcriptomic drug profiling to deliver precision therapeutics 11 Harnessing the power of transcriptome-wide profiling and novel chemistry to more efficiently develop drug candidates that have a higher probability of clinical success Our approa
Slide 12: HTG Life Sciences - the intersection of innovative profiling and chemistry
HTG Life Sciences - the intersection of innovative profiling and chemistry Four pillars to the platform 12 EdgeSeq Whole transcriptome mRNA and miRNA profiling guides drug discovery yielding architectures of health and disease HTG Epi-EdgeSeq Epi transcriptome profiling assessing m6A, A to I and oth
Slide 13: HTG drug discovery process
HTG drug discovery process 13 Iterative Development Candidate
Slide 14: HTG clinical process
HTG clinical process 14 Approval
Slide 15: Heat shock stress in cultured cells
15 Heat shock stress in cultured cells: Biological model of the impact of stress on RNA expression and modification. A combination of EdgeSeq and epiEdgeSeq allows: Robust measurement of RNA expression and RNA modification levels. Replication of published data. Discovery of additional modalities rel
Slide 16: IL-2 stimulation of Peripheral Blood Mononuclear Cells (PBMCs)
16 IL-2 stimulation of Peripheral Blood Mononuclear Cells (PBMCs): : Low-dose IL-2 stimulation preferentially activates regulatory T-cells and is a treatment of interest for cancer and autoimmune disorders. We investigated the impact of low-dose IL-2 treatment using PBMCs as a model. Combined EdgeSe
Slide 17: In Silico Chemistry Platform – Machine Learning
17 In Silico Chemistry Platform – Machine Learning mRNA, miRNA and epi-T profiling data guides small molecule drug discovery Machine learning compound design of focused small molecule library sets. Structure Based Ligand Based Pharmacophore Based 3-D Docking Technology to survey binding sites.
Slide 18: In Silico Chemistry Platform
In Silico Chemistry Platform 18
Slide 19: Pipeline
Pipeline Target Phenol MechineLeATING Gay paseg _HttoLend Lend RNA Targeted Disease Area Drug Program, plaids Discovery tts | eaitthn Screening Optimization Target 4 RMP Target 2 RMP Oncology Target e— Transcript Target 4 Stability Target 5 Muttipte Auto Immune Target 1 cena ens Target 4 TaD sre Die
Slide 20: The team
The team 20 John Lubniewski, Chief Executive Officer Ventana/Roche, Corning, Procter and Gamble Marian Navratil, SVP Research and Development Danaher, Beckman Coulter, University of Minnesota, Linkoping University Todd Huffman, VP of Strategy Padlock Therapeutics, Scripps, S6 Therapeutics, RCT, Univ
Slide 21: Examples in RNA therapeutics
21 Accent partners with Astra Zeneca in preclinical deal, $55M upfront, $1.1B in total milestones June, 2020 Arrakis Therapeutics partners with Roche for the discovery of RNA-targeted small molecule drugs against a broad set of targets across all of Roche’s research and development area, $190M upfro
Slide 22: Creating two categories of value
Creating two categories of value Hybrid business model 22 Platform Value (RNA profiling) Position EdgeSeq to accommodate expanding market demand for next generation transcriptome profiling ($1B market TAM): - Epi– Transcriptome – m6A, A to I, etc. - RNA Modifying Protein Panels - microRNAs - mRNAs -
Slide 23: HTG Molecular and HTG Therapeutics
HTG 23 HTG Molecular HTG Therapeutics HTG is a transcriptomics company developing novel drug candidates and profiling diagnostics to determine the right therapy for the right patient HTG Molecular – life science tools and diagnostics based on proprietary transcriptomic technologies and informatics H
HTG Molecular Diagnostics — Investor Presentation (July 2021) on 6ix